{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["50(12)"],"submitter":["Carvelli J"],"pubmed_abstract":["<h4>Objectives</h4>Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19.<h4>Design</h4>FOR COVID Elimination (FORCE) was a double-blind, placebo-controlled study.<h4>Setting</h4>Twelve clinical sites in France (ICU and general hospitals).<h4>Patients</h4>Patients receiving greater than or equal to 5 L oxygen/min to maintain Sp o2 greater than 93% (World Health Organization scale ≥ 5). Patients received conventional oxygen therapy or high-flow oxygen (HFO)/noninvasive ventilation (NIV) in cohort 1; HFO, NIV, or invasive mechanical ventilation (IMV) in cohort 2; and IMV in cohort 3.<h4>Interventions</h4>Patients were randomly assigned, in a 1:1 ratio, to receive avdoralimab or placebo. "],"journal":["Critical care medicine"],"pagination":["1788-1798"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9674430"],"repository":["biostudies-literature"],"pubmed_title":["Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])."],"pmcid":["PMC9674430"],"pubmed_authors":["Tilmont A","Demiselle J","Jacquier S","Dubief E","Le Gac S","Marrane G","Dhorne J","Bichon A","Benarous L","Mourissoux G","Langlade C","Nseir S","Chalal L","Dubois G","Lelievre JD","Le Tohic S","Chirio D","Deguenel-Nguyen A","Ebbo M","Coutard B","Vindrios W","Blondelon A","Clouzeau B","Schleinitz N","Monier A","Bourenne J","Bretagnol A","Mathonnet A","Kramer L","Lacombe K","Cauchois E","Vivier E","Fares J","Camou F","Vely F","Viotti J","Jandeaux LM","Carles M","Chauvel O","Bourhis M","Bezirganyan K","Jamet C","Piperoglou C","Coularet C","Guisset O","Delaune J","Bui HN","Bouzana F","Perreau P","Asselate B","Amichi K","Ducours M","Barthelemi L","Sebire M","Brice S","Carvelli J","Spadoni S","Merdji H","Issa N","Fleurot O","Bourgoin N","Clerc A","Demonchy E","De Nailly DL","Desclaux A","Julia Z","Deluca B","Tran C","Pedenon-Peyrichout D","Melica G","Lamarque J","Le Grand J","Veit V","Larosa A","Sanz C","Barbar SD","Boyer-Chammard A","Cohen A","Simeone P","Breaud S","Gainnier M","Pinglis C","Mai-Anh N","Bollens D","Kamel T","Gallien S","Thiemele A","Courjon J","Pastorino B","Buscot M","Karakunnel J","Helms J","Muller L","Bachelard A","Natella PA","Tellec S","Blasco V","Elotmani L","Cua E","Inal I","Servant V","Chouaki-Benmansour N","Oualit L","Ghezzoul B","Lehingue S","Meziani F","Velly L","Madjarian C","Plantefeve G","Barbier F","Boughdiri N","Thiebaut L","Provitolo V","Boyer A","Benzekri D","Dellamonica J","Da Conceicao O","Malvy D","Fraisse M","Rigault MC","Delcoutre C","Rotolo F","Allam H","FOR COVID Elimination (FORCE) Study Group","Batista L","Muller G","Rognon A","Meyrieux S","Lescure X","Ambert A","Pedeboscq S","Le Saux A","Gazoppi L","Papazian L","Cotellon C","Bouskila N","Garrido-Pradalie E","Savini H","Durieux F","Malkoun R","Runge I","Valera S","Djabarouti S","Le Dault E","Brunet J","Cordier PY","Guervilly C","Aouadenne-Mesbah A","Colombini N","Isernia V","Mariller L","Touitou I","Hutt-Clauss A","Allardet-Servent J","Villaroel MS","Demaria O","Salas V","Jean E","Benrezzak N","Letaillandier C","Poissy J","Bruder N","Saccheri C","Studer A","Javelle E","Kabala A","Davide Barbar S","Risso K","Le Garlantezec P","Desgrouas M","Poulet A","Forel JM","Lloret S"],"additional_accession":[]},"is_claimable":false,"name":"Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).","description":"<h4>Objectives</h4>Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19.<h4>Design</h4>FOR COVID Elimination (FORCE) was a double-blind, placebo-controlled study.<h4>Setting</h4>Twelve clinical sites in France (ICU and general hospitals).<h4>Patients</h4>Patients receiving greater than or equal to 5 L oxygen/min to maintain Sp o2 greater than 93% (World Health Organization scale ≥ 5). Patients received conventional oxygen therapy or high-flow oxygen (HFO)/noninvasive ventilation (NIV) in cohort 1; HFO, NIV, or invasive mechanical ventilation (IMV) in cohort 2; and IMV in cohort 3.<h4>Interventions</h4>Patients were randomly assigned, in a 1:1 ratio, to receive avdoralimab or placebo. ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-28T01:15:19.097Z","creation":"2024-10-18T22:38:10.342Z"},"accession":"S-EPMC9674430","cross_references":{"pubmed":["36218354"],"doi":["10.1097/CCM.0000000000005683"]}}